Pharmacokinetic study of triflusal in elderly subjects after single and repeated oral administration

American Journal of Therapeutics

Volumn 3, Issue 9, 1996, Pages 630-636

  Ferrari, E ^a   Reboldi, G ^b   Marenco, P ^a   D'Angelo, L ^a   Crema, R ^a   Ambrosoli, L ^c   Poli, A ^c   Girardello, R ^c   Lowenthal, D T ^d,e  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Poli Industria Chimica SpA   (Italy)

^d UNIVERSITY OF FLORIDA   (United States)

^e GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

Author keywords

aging; antiplatelet drugs; HTB; pharmacokinetics; triflusal

Indexed keywords

2 HYDROXY 4 (TRIFLUOROMETHYL)BENZOIC ACID; DRUG METABOLITE; TRIFLUSAL; UNCLASSIFIED DRUG;

AGED; AGING; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030002758     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199609000-00005     Document Type: Article

References (15)

1. Sànchez MS, Ramis J, Garcìa Rafanell J, Forn J: Comparative study of the ex-vivo inhibition of prostacyclin biosynthesis by triflusal and acetylsalicyclic acid. J Pharmacol 1983;14(4):600.
2. Sancho MJ, Castellarnau C, Vila L, Garcìa J, Carretéro F, Fabra A, Rutilant ML: Effects of salicylate derivatives on cyclooxygenase. Interaction studies. Biol Clin Hematol 1985;7:135-143.
3. Dominguez MJ, Vacas H, Saez Y, Olabarria I, Velasco A, Iriarte JA, Forn J: Effects of triflusal in patients with prosthetic heart valves. Clin Ther 1985;7(3):357-364.
4. Garcia Rafanell J, Planas JM, Puig-Parellada P Comparison of the inhibitory effects of acetylsalicyclic acid and triflusal on enzymes related to thrombosis. Arch Int Pharmacodyn Ther 1979;237(2):343-350.
5. Garcia Rafanell J, Ramis J, Gòmez L, Forn J: Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther 1986;284(1):155-165.
6. Ramis J, Torrent J, Mis R, Conte L, Barbanoj MJ, Jané J, Forn J: Pharmacokinetics of triflusal after single and repeated doses in man. Int J Clin Pharmacol Th 1990;28(8): 344-349.
7. Ramis J, Mis R, Forn J: Pharmacokinetics of triflusal and its main metabolite in rats and dogs. Eur J Drug Metab Pharmacokinet 1991;16(4):261-268.
8. Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jané F: Pharmakinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Eur J Drug Metab Pharmacokinet 1991a;16(4):269-273.
9. Mis R, Ramis J, Conte L, Forn J: In-vitro protein binding interaction between a metabolite of triflusal, 2-hydroxy4-trifluoromethylbenzoic acid and other drugs. J Pharm Pharmacol 1992;44:935-937.
10. Rimbau V, Forn J, Torralba A: Estudios de distribuciòn y metabolismo del triflusal. Arch Farmacol Toxicol 1982; 8(3):197-200.
11. Font L, Angelet P, Pérez V, Gonzàles A: Dosificatiòn del triflusal y estudio del efecto sobre la function plaquetaria en un grupo de pacientes en programa de hemodiàlisis. Biol Clin Hematol 1988;10:101-109.
12. Wagner JG: Fundamentals of Clinical Pharntacokinetics. Drug Intelligence Publications, Inc., Hamilton, IL, 1975.
13. Metzler CM, Weiner DL: PCNONLIN: User Guide. Statistical Consultants, Lexington, KY, 1985.
14. Gibaldi M, Perrier D: Pharmacokinetics, 2nd ed. Marcel Dekker, New York, 1982.
15. Jain A, McMahon FG, Slattery JT, Levy G: Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clin Pharmacol Ther 1979;25(1):61-66.